Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZ) Common Equity (2020 - 2026)

Core Scientific has reported Common Equity over the past 7 years, most recently at -$1.3 billion for Q1 2026.

  • Quarterly results put Common Equity at -$1.3 billion for Q1 2026, down 322.8% from a year ago — trailing twelve months through Mar 2026 was -$1.3 billion (down 322.8% YoY), and the annual figure for FY2025 was -$962.7 million, down 2.09%.
  • Common Equity reached -$1.3 billion in Q1 2026 per CORZ's latest filing, down from -$962.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $1.1 billion in Q1 2022 and bottomed at -$1.3 billion in Q1 2026.
  • Median Common Equity over the past 5 years was -$418.7 million (2023), compared with a mean of -$522.9 million.
  • The largest annual shift saw Common Equity surged 1059.68% in 2022 before it plummeted 673.39% in 2023.
  • Over 5 years, Common Equity stood at -$409.3 million in 2022, then tumbled by 45.83% to -$596.9 million in 2023, then tumbled by 57.98% to -$943.0 million in 2024, then decreased by 2.09% to -$962.7 million in 2025, then plummeted by 35.62% to -$1.3 billion in 2026.
  • Business Quant data shows Common Equity for CORZ at -$1.3 billion in Q1 2026, -$962.7 million in Q4 2025, and -$1.3 billion in Q3 2025.